

Angiogenesis in *Schistosoma haematobium*-associated urinary bladder cancer

ANDERSON DEMATEI,¹ RÚBEN FERNANDES,^{1,2} RAQUEL SOARES,^{2,3} HELENA ALVES,^{4,5} JOACHIM RICHTER⁶ and MONICA C. BOTELHO^{2,4}

¹Ciências Químicas e das Biomoléculas, Escola Superior de Saúde, Instituto Politécnico do Porto; ²I3S, Instituto de Investigação e Inovação da Universidade do Porto; ³Departamento de Biomedicina, Unidade de Bioquímica, Faculdade de Medicina, Universidade do Porto; ⁴Department of Health Promotion and Chronic Diseases, INSA – National Institute of Health Dr. Ricardo Jorge, Porto; ⁵Fundação Professor Ernesto Morais, Porto, Portugal; and ⁶Institute of Tropical Medicine and International Health, Charité – Universitätsmedizin Berlin, Berlin, Germany

Mónica C. Botelho, Department of Health Promotion and Chronic Diseases, INSA – National Institute of Health Dr. Ricardo Jorge, Rua Alexandre Herculano 321, Porto 4000-055, Portugal. e-mails: monicabotelho@hotmail.com; monica.botelho@insa.min-saude.pt

Schistosoma haematobium, a parasitic flatworm that infects more than 100 million people, mostly in the developing world, is the causative agent of urogenital schistosomiasis, and is associated with a high incidence of squamous cell carcinoma (SCC) of the bladder. During infection, eggs are deposited in the bladder causing an intense inflammatory reaction. Angiogenesis is defined as the formation of new blood vessels from preexisting ones and is recognized as a key event in cell proliferation and carcinogenesis and spread of malignant lesions. A growing amount of evidence points to angiogenesis playing a key role in schistosomiasis-associated bladder cancer. Thus, identifying biomarkers of this process plays an important role in the study of cancer. Here, we review recent findings on the role of angiogenesis in bladder cancer and the growth factors that induce and assist in their development, particularly SCC of the bladder associated to urogenital schistosomiasis.

Key words: Schistosomiasis; urothelial carcinoma; blood vessels; urogenital schistosomiasis; angiogenic markers.

SCHISTOSOMIASIS

Schistosomiasis is a neglected tropical disease transmitted to humans from freshwater snails. It is caused by a blood fluke of the genus *Schistosoma*. Schistosomiasis is considered the most important of the helminthiases and the second most important parasitosis, after malaria, causing high rates of morbidity and mortality. As of 1989, schistosomiasis was endemic in 76 countries (1). Recent WHO report declared schistosomiasis endemic in 78 countries (2, 3). *S. haematobium* is endemic in 53 countries in the Middle East and most of the African continent, including the islands of Madagascar and Mauritius. Due to successful eradication programs,

the infection is no more of significant public health significance in Egypt, Lebanon, Oman, Syria, Tunisia and Turkey because transmission is low or nonexistent (4). A disputed and ill-defined focus exists in India and requires further confirmation (5). After more than 50 years in which no more autochthonous cases of schistosomiasis were recorded in Europe, *S. haematobium* infection has recently emerged in Corsica (6). This disease affects 200 million people worldwide. From these, 20 million have severe disease and 120 million are considered symptomatic. Risk of infection affects 600 million; others including travelers from developed countries (7).

This review focuses on the morphological variables and prognosis in carcinoma of the urinary bladder associated with schistosomiasis, and the

fact that the appearance and formation of angiogenesis alters the course of cancer development, in the context of *S. haematobium* infection. The present work attempts to integrate a variety of studies and experimental approaches with *S. haematobium* models, while giving particular emphasis to the *in vitro* studies that have contributed to expanding our understanding of the mechanisms of action of growth factors and formation of new vessels in urinary bladder cancer. In particular, we suggest that the presence of eggs of *S. haematobium* plays a key role in angiogenesis and contributes to the development of urinary bladder cancer (Fig. 1).

UROGENITAL SCHISTOSOMIASIS

Three major species of schistosomes are the agents of human schistosomiasis – *Schistosoma japonicum* and *Schistosoma mansoni* cause intestinal

schistosomiasis in East Asia, Africa, South America and the Caribbean, while *S. haematobium*, occurring widely throughout Africa and the Middle East, causes urogenital schistosomiasis. Recent recalibration of health burdens revealed that in the range of 4.5–70 million disability adjusted life years (DALYs) are lost to schistosomiasis. More people are infected with *S. haematobium* than with the other schistosomes combined. Of 112 million cases of *S. haematobium* infection in sub-Saharan Africa, 70 million are associated with hematuria, 18 million with major urinary bladder wall pathology, and 10 million with hydronephrosis leading to kidney damage (8–10). In many patients, deposition of *S. haematobium* parasite ova eventually leads to squamous cell carcinoma (SCC) of the urinary bladder (11, 12). Accordingly, *S. haematobium* has been classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC) (13, 14).




Fig. 1. Schematic representation of angiogenesis associated with urogenital schistosomiasis. Microphotographs from urinary bladder sections stained with Hematoxylin and Eosin (400×).

SCHISTOSOMA HAEMATOBIIUM- ASSOCIATED URINARY BLADDER CANCER

Squamous cell carcinoma is a malignant, poorly differentiated neoplasm. SCC is the common form of urinary bladder cancer in rural Africa where *S. haematobium* is prevalent (15, 16). By contrast, the majority of urinary bladder cancer in developing countries and regions not endemic for urogenital schistosomiasis is transitional cell carcinoma (TCC), which arises from the transitional epithelium lining of the urinary bladder. The parasite eggs trapped in the urinary bladder wall release antigens and other metabolites (presumably evolved to expedite egress to the urine, and hence to the external environment). The phenomenon leads to hematuria and to chronic inflammation, in turn increasing the risk of SCC of the urinary bladder. The epidemiological association between SCC of the urinary bladder with schistosomiasis hematobia is based both on case-control studies and on the correlation of urinary bladder cancer incidence with prevalence of *S. haematobium* infection within diverse geographic locations. The incidence of urogenital schistosomiasis-associated SCC is estimated in 3–4 cases per 100 000 (17). Schistosomiasis hematobia is a chronic infection. The adult, egg-producing schistosomes live for many years, re-infections frequently occur, and schistosomiasis-associated urinary bladder SCC appears relatively early, often by the mid-decades of life (TCC usually presents in the later decades of life). In its most recent monograph, IARC confirmed that chronic infection with *S. haematobium* causes cancer of the urinary bladder (14).

The cellular and molecular mechanism linking infection with *S. haematobium* and cancer is usually related to adult parasite invasion in the venous plexus around the urinary bladder, the eggs released by worms, cause chronic granulomatous inflammation of the mucosa and submucosa of the urinary bladder. Chronic granulomatous inflammation and irritation subsequently leads to the development of squamous metaplasia of the transitional epithelium. Chronic granulomatous inflammation also leads to fibrosis in the urinary bladder that causes urinary stasis and super-infection by bacteria. The bacteria convert the nitrates and nitrites in dietary nitrosamines, which are then excreted in urine. These nitrosamines are carcinogenic and acting on metaplastic epithelium, promote subsequent progression of squamous cell carcinoma. The infection can spread and involve the ureters and kidneys, causing chronic obstructive disorders and kidney failure (18). Several models have been proposed to explain the genesis of urinary bladder

cancer induced by Urogenital Schistosomiasis (UGS). Some attribute initiation of carcinogenesis to low doses of nitrosamines and/or other environmental carcinogens associated with the infection. In other models, it is suggested that UGS-induced carcinogenesis is due to exposure to tobacco smoke, industrial and agricultural dyes and vitamin A deficiency (19). However, the mechanism by which infection contributes to carcinogenesis is still unresolved. Recent contributions suggest a crucial role of *S. haematobium*: Chinese Hamster Ovary cells (CHO) cells experimentally treated with parasite antigens show increased proliferation, cell migration and invasion, decreased apoptosis, increased Bcl-2 expression and reduced p27 expression. Altogether, these biological processes are characteristic of tumorigenesis and tumor cell survival (7). Further, intravesical administration in a murine model of *S. haematobium* extract induces urothelial dysplasia (20), implying that infection by *S. haematobium* induces malignant transformation of the urothelium, even in the absence of nitrosamines. Previous reports of our group revealed that schistosomes produce estrogen metabolites called catechols and that these molecules can be used as biomarkers for the detection of schistosomiasis-associated urinary bladder cancer (21–23). Based on this scientific evidence, and the discovery of parasitic origin of estrogen metabolites, becomes fundamental to understanding the role of this parasite as initiator of carcinogenesis (24).

ANGIOGENESIS AND LYMPHANGIOGENESIS IN URINARY BLADDER CANCER

Angiogenesis, or the formation of new endothelial sprouts from preexisting postcapillary venules, is a well-known characteristic of inflammatory diseases, wound repair and cancer (25, 26). Accordingly, angiogenesis is a process in which endothelial cells migrate and divide to form new capillaries, providing support for tumor progression. As such, much attention has been focused on pathological significance and detailed mechanism of the vascular system and angiogenesis in cancer. Moreover, the spread of tumor cells through the bloodstream and lymphatic system plays an important role in metastases development (26). A large number of pro-angiogenic factors including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF) and angiogenin (ANG) are often overexpressed in tumors (27). Several studies have indicated that angiogenic activators play an important part in the

growth and spread of tumors. On immunohistochemical examination, the VEGF family and their receptors were found to be expressed in about half of the human cancers investigated (28). These factors are known to affect the prognosis of adenocarcinomas that have developed in the uterine cervix, (29), endometrium, (30), ovary (31) and stomach (32). In addition, a significant correlation between the expression of VEGF and prognosis has been described in colorectal cancer (33), breast cancer (34), lung cancer (35), head and neck squamous cell carcinoma (36), Kaposi sarcoma (37) and malignant mesothelioma (38). These studies also indicated that the levels of angiogenic factors in tissue reflect the aggressiveness with which tumor cells spread, and thus have predictive value in the identification of the high-risk patients with poor prognosis.

Metastatic spread to regional lymph nodes is an early step in systemic dissemination of tumors, being usually associated with poor survival (39). Moreover, exacerbated angiogenesis together with presence of lymph node metastasis are poor prognostic factors for transitional cell carcinoma and urinary bladder carcinoma (40).

While both the blood and lymphatic vascular systems have been implicated, preclinical experimental systems supported by clinical evidence suggest the most common pathway of initial metastasis is through the lymphatic system (41). In recent years, several works discuss the importance of pathological lymphangiogenesis in urinary bladder cancer and in its importance in the invasiveness toward adjacent muscle tissue (42–44). Similarly, recent reports evidence the activation of VEGF signaling that controls and promotes lymphangiogenesis by several parasites such as filariasis and leishmaniasis agents (45, 46). Although lymphangiogenesis is shown to be increased in both urinary bladder cancer and in infection caused by parasites, it is a question needed to be answered whether lymphangiogenesis would be involved in urinary bladder cancer associated with schistosomiasis.

SCHISTOSOMIASIS AND ANGIOGENESIS

Angiogenesis plays a complex and extraordinary role in schistosomiasis. This statement may seem a paradox, since schistosomes are intravascular parasites that cause damage by destroying the blood vessels (47). Angiogenesis plays an important role during the formation of perioval granulomas as well as in the genesis of schistosomiasis fibrosis. From the point of view of general pathology, schistosomal perioval granulomas are dynamically similar to the healing of wounds, with the production

of granulation tissue, which becomes increasingly less vascularized with time (48).

It has been demonstrated that intact live eggs, excretory/secretory products of eggs and the extracts of homogenized eggs stimulate the proliferation and migration of endothelial cells. Formation of endothelial capillary-like outgrowths, was stimulated by egg extracts (49). The effects mediated by eggs of schistosomes revealed that the soluble egg antigen induces endothelial cell proliferation and upregulates vascular endothelial growth factor (VEGF) (47). Loeffler et al. (50) investigated the effects of *Schistosoma mansoni* soluble egg antigen (SEA) on angiogenic processes: proliferation, tube formation and apoptosis of human umbilical vein endothelial cells (HUVECs). In this study, SEA increased HUVEC tube formation and decreased HUVEC apoptosis after serum and growth factor deprivation. These authors showed that messenger RNA for vascular endothelial growth factor (VEGF) increased 2-fold in SEA-treated HUVECs. Their findings suggest that products secreted by schistosome eggs may promote angiogenesis by upregulating endothelial cell VEGF (50). Other authors analyzed VEGF levels in sera from people diagnosed with schistosomiasis. These patients had significantly high VEGF levels compared with healthy people (51, 52). Therefore, this angiogenic capacity has been suggested as an early marker of preneoplastic and neoplastic lesions in schistosomiasis associated SCC (53). Several growth factors and other molecules produced by the schistosome itself have been reported to be associated with tumor growth, progression and survival of urinary bladder cancer. Moreover, tumor microvessel density (MVD) is thought to be the most useful prognostic marker for cancer development, the relapse-free survival and overall survival (54). El-Sobky and collaborators (55) found a significant relationship between angiogenesis and tumor grade. These findings suggest that assessing angiogenesis using the MVD provides an independent predictor of survival in patients with schistosome-associated carcinoma of the urinary bladder.

Studies to quantify the concentration of angiogenic factors in cases of SCC of the urinary bladder associated to schistosomiasis may be of great clinical importance for urinary bladder cancer detection, assessing their stage and level of development. The methodologies that can be performed to evaluate angiogenesis associated with *S. haematobium* infection are by means of microscopy/immunochemical, ELISA, PCR-based techniques and other molecular biology techniques that can be used to evaluate vascularization markers in both samples of infected patients and in animal models. Such markers may

include CD31, CD34, vonWillebrand factor (vWF) and VGFRs. Angiogenic markers showed significant association with clinical stage (27). It was reported that Basic fibroblast growth factor (bFGF) increased significantly in urinary bladder squamous cell carcinoma cases. These authors found that bFGF and hepatocyte growth factor (HGF) significantly correlated with tumor grade (27). Understanding the growth factors that influence the progression of angiogenesis and lymphangiogenesis during infection by schistosomes becomes feasible from the point of view of a possible intervention in the spread of tumor cells. Moreover, cancers are genetically diversified using different exposures, DNA repair effects and cellular origin, which may suggest that a particular exposure (parasite antigen) can lead to a cascade of events that promote cancer in susceptible hosts, and that angiogenic factors, as reported in *S. haematobium*, could be used as diagnostic and prognostic markers of urinary bladder cancer in UGS. In the case of Symmers' fibrosis associated to schistosomiasis, angiogenesis inhibitors are indicated as an effective tool for the treatment of this liver fibrosis (55).

CONCLUDING REMARKS AND FUTURE PERSPECTIVES

In the last years, urinary bladder cancer-associated schistosomiasis has been a field under extensive investigation. Increasing knowledge in the field has opened up important new perspectives with respect to how this type of cancer is perceived. Among them, there are crucial findings on the hallmarks of cancer and the contribution of these to the carcinogenic process, specially angiogenesis and lymphangiogenesis. On the basis of these results, a new mechanistic approach to the development of schistosomiasis-associated urinary bladder cancer arose, enabling us to further comprehend their underlying molecular mechanisms and contribution to the development of this type of cancer. Studies are needed to identify and characterize angiogenic and lymphangiogenic markers in carcinoma of the urinary bladder associated to UGS. Tumor induction, proliferation, invasion and metastasis represent a complex and incompletely understood series of events (56). Thus, the development of additional biological markers of prognosis for tumor angiogenesis and lymphangiogenesis, may add information to the initial risk assessment. It is to be hoped that the rapidly increasing volume of information in these field can be used in the future to develop specific and more effective anti-cancer therapies, not only toward schistosomiasis-

associated urinary bladder cancer but also other types of cancer.

REFERENCES

1. Mott KE. Contrasts in the control of schistosomiasis. *Mem Inst Oswaldo Cruz* 1989;84:3–19.
2. World Health Organization. Weekly epidemiological record, 90th year, 2015; 90, 25–32. <http://www.who.int/wer>
3. WHO. Schistosomiasis: Progress Report 2001–2011, Strategic Plan 2012–2020. Geneva: World Health Organization, 2013.
4. Botelho MC, Alves H, Richter J. Halting *Schistosoma haematobium*-associated bladder cancer. *Ira J Can Prev* (in press).
5. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis and estimates of people at risk. *Lancet Infect Dis* 2006;6:411–425.
6. Holtfreter MC, Moné H, Müller-Stöver I, Mouahid G, Richter J. *Schistosoma haematobium* infections acquired in Corsica, France, August 2013. *Euro Surveill* 2014;19: pii 20821.
7. Botelho MC, Vale N, Gouveia MJ, Rinaldi G, Santos J, Santos LL, et al. Tumour-like phenotypes in urothelial cells after exposure to antigens from eggs of *Schistosoma haematobium*: an oestrogen-DNA adducts mediated pathway? *Int J Parasitol* 2013;43:17–26.
8. van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop* 2003;86: 125–39.
9. Hotez PJ, Fenwick A, Kjetland EF. Africa's 32 cents solution for HIV/AIDS. *PLoS Negl Trop Dis* 2009;3: e430.
10. King CH. Parasites and poverty: the case of schistosomiasis. *Acta Trop* 2010;113:95–104.
11. Hodder SL, Mahmoud AA, Sorenson K, Weinert DM, Stein RL, Ouma JH, et al. Predisposition to urinary tract epithelial metaplasia in *Schistosoma haematobium* infection. *Am J Trop Med Hyg* 2000;63:133–8.
12. Parkin DM. The global health burden of infection-associated cancers in the year 2002. *Int J Cancer* 2006;118:3030–44.
13. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El GHISSASSI F, et al. A review of human carcinogens – Part B: biological agents. *Lancet Oncol* 2009;10:321–2.
14. IARC, Biological agents. Volume 100 B. A review of human carcinogens. *IARC Monogr Eval Carcinog Risks Hum* 2012;100(Pt B):1–441.
15. Mostafa MH, Sheweita SA, O'Connor PJ. Relationship between schistosomiasis and bladder cancer. *Clin Microbiol Rev* 1999;12:97–111.
16. Zhong X, Isharwal S, Naples JM, Shiff C, Veltri RW, Shao C, et al. Hypermethylation of genes detected in urine from Ghanaian adults with bladder pathology associated with *Schistosoma haematobium* infection. *PLoS One* 2013;8:e59089.
17. Shiff C, Veltri R, Naples J, Quartey J, Otchere J, Anyan W, et al. Ultrasound verification of bladder damage is associated with known biomarkers of

- bladder cancer in adults chronically infected with *Schistosoma haematobium* in Ghana. *Trans R Soc Trop Med Hyg* 2006;100:847–54.
18. Rambau PF, Chalya PL, Jackson K. Schistosomiasis and urinary bladder cancer in North Western Tanzania: a retrospective review of 185 patients. *Infect Agent Cancer* 2013;8:19.
 19. Honeycutt J, Hammam O, Fu CL, Hsieh MH. Controversies and challenges in research on urogenital s. Controversies and challenges in research on urogenital schistosomiasis-associated bladder cancer. *Trends Parasitol* 2014;30:324–32.
 20. Botelho MC, Oliveira PA, Lopes C, Correia da Costa JM, Machado JC. Urothelial dysplasia and inflammation induced by *Schistosoma haematobium* total antigen instillation in mice normal urothelium. *Urol Oncol* 2011;29:809–14.
 21. Botelho MC, Alves H, Barros A, Rinaldi G, Brindley PJ, Sousa M. The role of estrogens and estrogen receptor signaling pathways in cancer and infertility: the case of schistosomes. *Trends Parasitol* 2015;31:246–50.
 22. Botelho MC, Alves H, Richter J. Estrogen metabolites for the diagnosis of schistosomiasis associated urinary bladder cancer. *SM Trop Med J* 2016;1:1004
 23. Botelho MC, Alves H, Richter J. Estrogen catechols detection as biomarkers in schistosomiasis induced cancer and infertility. *Lett Drug Des Discov* 2017;14:135–8
 24. Botelho MC, Teixeira JP, Oliveira PA. Carcinogenesis, In: Wexler P, editor. *Encyclopedia of Toxicology* (3rd edn). Oxford: Academic Press, 2014: 713–29.
 25. Van de Vijver KK, Colpaert CG, Jacobs W, Kuypers K, Hokke CH, Deelder AM, et al. The host's genetic background determines the extent of angiogenesis induced by schistosome egg antigens. *Acta Trop* 2006;99:243–51.
 26. Miyata Y, Kanda S, Ohba K, Nomata K, Hayashida Y, Eguchi J, et al. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. *Clin Cancer Res* 2006;12:800–6.
 27. Eissa S, Swellam M, Labib RA, El-Zayat T, El Ahmady O. A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot. *J Urol* 2009;181:1353–60.
 28. Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. *Thromb Haemost* 1998;80:171–5.
 29. Hashimoto I, Kodama J, Seki N, Hongo A, Yoshinouchi M, Okuda H, et al. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. *Br J Cancer* 2001;85:93–7.
 30. Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. *Gynecol Oncol* 2001;80:181–8.
 31. Nishida N, Yano H, Komai K, Nishida T, Kamura T, Kojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. *Cancer* 2004;101:1364–74.
 32. Amioka T, Kitadai Y, Tanaka S, Haruma K, Yoshihara M, Yasui W, et al. Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. *Eur J Cancer* 2002;38:1413–9.
 33. Furudoi A, Tanaka S, Haruma K, Kitadai Y, Yoshihara M, Chayama K, et al. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. *Oncology* 2002;62:157–66.
 34. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. *Nat Med* 2001;7:192–8.
 35. Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, Tsunozuka Y, et al. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. *Br J Cancer* 2001;85:255–60.
 36. O-charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. *Cancer* 2001;92:556–68.
 37. Jussila L, Valtola R, Partanen TA, Salven P, Heikkilä P, Matikainen MT, et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. *Cancer Res* 1998;58:1599–604.
 38. Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. *Br J Cancer* 1999;81:54–61.
 39. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. *Nat Rev Cancer* 2002;2:573–83.
 40. Elsobky E, El-Baz M, Gomha M, Abol-Enein H, Shaaban AA. Prognostic value of angiogenesis in schistosoma-associated squamous cell carcinoma of the urinary bladder. *Urology* 2002;60:69–73.
 41. Christiansen A, Detmar M. Lymphangiogenesis and cancer. *Genes Cancer* 2011;2:1146–58.
 42. Matsuo T, Miyata Y, Mitsunari K, Yasuda T, Ohba K, Sakai H. Pathological significance and prognostic implications of heme oxygenase 1 expression in non-muscle-invasive bladder cancer: correlation with cell proliferation, angiogenesis, lymphangiogenesis and expression of VEGFs and COX-2. *Oncol Lett* 2017;13:275–80.
 43. Khadim MT, Ahmed SA, Khan FA, Ikram A, Shaikh SY. Evaluation of vascular endothelial growth factors A, C and D as indicators of lymphangiogenesis and angiogenesis in invasive and non-invasive urothelial carcinoma bladder. *J Pak Med Assoc* 2015;65:851–6.
 44. Fernández MI, Bolenz C, Trojan L, Steidler A, Weiss C, Alken P, et al. Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder. *Eur Urol* 2008;53:571–8.
 45. Weinkopf T, Konradt C, Christian DA, Discher DE, Hunter CA, Scott P. Leishmania major infection-induced VEGF-A/VEGFR-2 signaling promotes lymphangiogenesis that controls disease. *J Immunol* 2016;197:1823–31.
 46. Chakraborty S, Gurusamy M, Zawieja DC, Muthuchamy M. Lymphatic filariasis: perspectives on

- lymphatic remodeling and contractile dysfunction in filarial disease pathogenesis. *Microcirculation* 2013;20:349–64.
47. Andrade ZA, Santana TS. Angiogenesis and schistosomiasis. *Mem Inst Oswaldo Cruz* 2010;105:4.
 48. Botelho MC, Alves H, Richter J. Wound healing and cancer progression in *Opisthorchis viverrini* associated cholangiocarcinoma. *Parasitol Res* 2016;115:2913–4.
 49. Kanse SM, Liang O, Schubert U, Haas H, Preissner KT, Doenhoff MJ, et al. Characterisation and partial purification of *Schistosoma mansoni* egg-derived pro-angiogenic factor. *Mol Biochem Parasitol* 2005;144:76–85.
 50. Loeffler DA, Lundy SK, Singh KP, Gerard HC, Hudson AP, Boros DL. Soluble egg antigens from *Schistosoma mansoni* induce angiogenesis-related processes by up-regulating vascular endothelial growth factor in human endothelial cells. *J Infect Dis* 2002;185:1650–6.
 51. Tawfeek GM, Alafifi AM, Azmy MF. Immunological indicators of morbidity in human schistosomiasis mansoni: role of vascular endothelial growth factor and anti-soluble egg antigen IgG4 in disease progression. *J Egypt Soc Parasitol* 2003;33:597–614.
 52. Shariati F, Pérez-Arellano JL, Carranza C, López-Abán J, Vicente B, Arefi M, et al. Evaluation of the role of angiogenic factors in the pathogenesis of schistosomiasis. *Exp Parasitol* 2011;128:44–9.
 53. Machicado C, Marcos LA. Carcinogenesis associated with parasites other than *Schistosoma*, *Opisthorchis* and *Clonorchis*: a systematic review. *Int J Cancer* 2016;138:2915–21.
 54. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. *Br J Urol* 1994;74:762–6.
 55. El Sobky E, Gomha M, El-Baz M, Abol-Enein H, Shaaban AA. Prognostic significance of tumour angiogenesis in schistosoma-associated adenocarcinoma of the urinary bladder. *BJU Int* 2002;89:126–32.
 56. Croquet V, Moal F, Veal N, Wang J, Oberti F, Roux J, et al. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. *J Hepatol* 2002;37:773–80.